(NASDA SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by HC Wainwright & Co. on May 12, 2025. The analyst firm set a price target for $75.00 expecting GPCR to rise to ...

In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...

G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

No description, website, or topics provided.

星形胶质细胞如何调节神经环路是神经生物学的基本问题。来自不同研究的人员利用果蝇、斑马鱼、小鼠等模型，研究星形胶质细胞 - 神经元通讯机制，发现 G 蛋白偶联肾上腺素能信号可 “门控” 星形胶质细胞对神经递质的反应，该机制或具普遍性，为相关 ...

A novel GPS NMR method enabled precise tracking of motions within the β 1-adrenergic GPCR, revealing that the receptor exists in a dynamic equilibrium among inactive, preactive, and active states.